Key Highlights
- Cathie Wood’s ARK Invest divested 39,362 shares of Bullish (BLSH) valued at approximately $1.56 million on March 23 through its ARKK and ARKW portfolios
- Bullish shares advanced 4.16% during the same trading session, settling near $39.55
- The investment firm previously liquidated 103,379 BLSH shares for approximately $3.93 million on March 20
- ARK accumulated around 2.1 million BLSH shares worth approximately $58–$60 million during a nine-day period in February 2026
- Wall Street maintains a Moderate Buy rating on BLSH with a consensus price target of $47.83, suggesting potential upside of approximately 20.9%
Cathie Wood’s investment firm reduced its Bullish (BLSH) position by 39,362 shares on Monday, March 23, representing approximately $1.56 million in value, while shares appreciated 4.16% during the session.
The divestment occurred across two exchange-traded funds: ARK Innovation ETF (ARKK) reduced its holdings by 31,154 shares, while ARK Next Generation Internet ETF (ARKW) sold 8,208 shares. The stock concluded trading at $39.55.
The March 23 transaction followed an earlier divestment. Three days prior, on March 20, ARK liquidated 103,379 BLSH shares representing approximately $3.93 million — a substantially larger reduction that received less attention than Monday’s activity.
Combining both transactions yields 142,741 shares sold, representing roughly $5.5 million in total value. ARK maintains a substantial position accumulated through months of concentrated acquisition activity.
During February 2026, ARK executed a nine-day accumulation campaign in BLSH, acquiring approximately 2.1 million shares for roughly $58–$60 million. These purchases occurred following a post-earnings decline in share price.
Financial Performance Overview
Bullish delivered fourth-quarter 2025 adjusted revenue of $92.5 million alongside adjusted EBITDA of $44.5 million, representing year-over-year growth. The company recorded a net loss of $563.6 million, while adjusted net income improved to $28.9 million.
Digital asset sales totaled $64.3 billion during the quarter, reflecting a modest decrease. Management provided 2026 guidance for subscription, services, and other revenue in the range of $220 million to $250 million.
Full-year adjusted operating expenses are projected to range between $210 million and $230 million.
Understanding the Portfolio Adjustment
The recent divestment appears tactical rather than reflecting a fundamental shift in outlook. ARK Invest has consistently accumulated BLSH shares during price weakness and reduced positions during strength — Monday’s transaction aligns perfectly with this pattern, coinciding with a 4%-plus gain.
ARK is simultaneously reallocating capital toward biotechnology opportunities. On the same day, the firm purchased 98,722 shares of 10X Genomics (TXG) worth $1.89 million, while TXG also posted a 4.08% gain.
Cryptocurrency-related equities like BLSH typically exhibit significant volatility correlated with Bitcoin price movements and regulatory developments, making them logical candidates for strategic profit-taking following strong performance.
TipRanks data shows BLSH maintains a Moderate Buy consensus rating supported by four Buy recommendations and two Hold ratings. Wall Street analysts project an average price target of $47.83, representing potential upside of approximately 20.9% from current trading levels.
